Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1522466 | 0.85 | PTGES2 (0.48) | ACMSDHDAC2HDAC1BACE1HDAC4 | |
| SCHEMBL20093001 | 0.79 | TYK2 (0.38) | ACMSDHDAC2HDAC1BACE1HDAC3 | |
| SCHEMBL7952462 | 0.75 | PTGS2 (0.51) | ACMSDHDAC2HDAC1BACE1HDAC4 | |
| SCHEMBL20092262 | 0.75 | HDAC1 (0.39) | HDAC2HDAC1HDAC3 | |
| SCHEMBL14454641 | 0.75 | HDAC1 (0.42) | HDAC2HDAC1HDAC3 | |
| SCHEMBL15156130 | 0.73 | BACE1 (0.49) | ACMSDHDAC2HDAC1BACE1HDAC4 | |
| SCHEMBL3985023 | 0.71 | BACE1 (0.51) | ACMSDHDAC2HDAC1BACE1HDAC3 | |
| SCHEMBL30490281 | 0.71 | HDAC1 (0.40) | HDAC2HDAC1PTGES2HDAC3LMNA | |
| SCHEMBL9297221 | 0.70 | ACMSD (0.57) | ACMSDHDAC2HDAC4HDAC8PTGES2 | |
| SCHEMBL25289702 | 0.70 | HDAC1 (0.36) | HDAC2HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235548-B2 | Compounds and their use as positive AMPA receptor modulators | NEUROSEARCH A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| US-6943159-B1 | Compounds and their use as positive AMPA receptor modulators | NEUROSEARCH A/S (DK) | 2005-09-13 | — | — | US | disclosed |
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | NEUROSEARCH A/S. | 2004-03-04 | — | — | US | disclosed |
| EP-1071426-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999042456-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | GRIK4, GRIA4, GRM2 | ACMSD 2885/4885HDAC2 703/4885HDAC1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.